Exploring the role of neuropeptides in depression and anxiety
Exploring the role of neuropeptides in depression and anxiety
复制标题
DOI：
10.1016/j.pnpbp.2021.110478
复制
发表时间：
2021-11-30
影响因子：
5.6
通讯作者：
Bungau, Simona
中科院分区：
文献类型：
--
作者：
Rana, Tarapati;Behl, Tapan;Bungau, Simona
抑郁症是最普遍的精神障碍之一，也是西方世界最常见的致残原因。此外，与压力相关的情绪障碍对患者本身的有害影响，它们对医疗保健系统构成了巨大的社会和经济影响。由于患者对现有药物无反应的比例很高，寻找新的治疗策略已成为神经生物学的重要课题，并且有大量证据表明神经肽不仅参与应激生理，而且可能在临床上具有重要意义。基于临床前试验数据，新的神经药物候选物可能针对神经肽及其受体，并有望成为治疗精神疾病的重要和有价值的工具。在这篇文章中，我们总结了抑郁症动物模型和转基因小鼠模型的数据。我们还重点关注促肾上腺皮质激素释放激素（CRH）、甘丙肽（GAL）、神经肽Y （NPY）、神经肽S （NPS）、催产素（OXT）、抗利尿素（VP）、胆囊收缩素（CCK）、黑色素浓缩激素（MCH）应激研究领域的前期临床研究数据。
Depression is one of the most prevalent forms of mental disorders and is the most common cause of disability in the Western world. Besides, the harmful effects of stress-related mood disorders on the patients themselves, they challenge the health care system with enormous social and economic impacts. Due to the high proportion of patients not responding to existing drugs, finding new treatment strategies has become an important topic in neurobiology, and there is much evidence that neuropeptides are not only involved in the physiology of stress but may also be clinically important. Based on preclinical trial data, new neuropharmaceutical candidates may target neuropeptides and their receptors and are expected to be essential and valuable tools in the treatment of psychiatric disorders. In the current article, we have summarized data obtained from animal models of depressive disorder and transgenic mouse models. We also focus on previously published research data of clinical studies on corticotropin-releasing hormone (CRH), galanin (GAL), neuropeptide Y (NPY), neuropeptide S (NPS), Oxytocin (OXT), vasopressin (VP), cholecystokinin (CCK), and melanin-concentrating hormone (MCH) stress research fields.